Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial f…
Biotechnology
US, Redwood City [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -83.39 | -35.63 | -19.43 | |
| Graham Fair Price | -29.40 | 12.88 | 18.25 | |
| PEG | -29.55 | 0.29 | -0.41 | |
| Price/Book | 36.41 | 3.02 | 2.22 | |
| Price/Cash Flow | 3.27 | -31.87 | -32.95 | |
| Prices/Earnings | -79.47 | -11.25 | -6.27 | |
| Price/Sales | inf | 0.00 | 5457.08 | |
| Price/FCF | 3.27 | -31.87 | -32.95 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Somewhat Weak
Fundamentals
Profitability
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | inf | 0.00 | -2.85 | |
| Operating Margin | inf | 0.00 | -242.56 | |
| ROA | 21.41 | -0.06 | -0.08 | |
| ROE | -0.09 | -0.07 | 24.00 | |
| ROIC | -0.09 | -0.08 | 19.53 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | < 0.005 | 0.40 | -99.76 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -0.46 | 0.22 | -52.78 | |
| EPS QOQ | -0.15 | 0.39 | 154.74 | |
| FCF QOQ | -0.19 | -0.33 | -72.56 | |
| Revenue QOQ | 0.00 | -1.00 | -100.00 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Weak
Fundamentals
Leverage & Liquidity
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | < 0.005 | 0.00 | inf | |
| Days Sales Outstanding (DSO) | 152.10 | 0.00 | inf | |
| Inventory Turnover | 2858000.00 | 0.00 | inf | |
| Debt/Capitalization | 0.05 | 0.05 | 5.65 | |
| Quick Ratio | 12.89 | 18.18 | 41.01 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | 12.93 | 10.47 | -19.02 | |
| Cash | 13.12 | 10.34 | -21.20 | |
| Capex | -0.02 | -0.02 | -17.15 | |
| Free Cash Flow | -0.87 | -0.99 | -14.20 | |
| Revenue | < 0.005 | 0.00 | inf | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad